ID: ALA5200950

Max Phase: Preclinical

Molecular Formula: C22H19F3N4O3SSe

Molecular Weight: 555.44

Representations

Canonical SMILES:  Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(=O)(=O)NC(=O)CCC[Se]C#N)cc2)cc1

Standard InChI:  InChI=1S/C22H19F3N4O3SSe/c1-15-4-6-16(7-5-15)19-13-20(22(23,24)25)27-29(19)17-8-10-18(11-9-17)33(31,32)28-21(30)3-2-12-34-14-26/h4-11,13H,2-3,12H2,1H3,(H,28,30)

Standard InChI Key:  JLXAJJYWGPXHET-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 555.44

Molecular Weight (Monoisotopic): 556.0295

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Liu J, Zhang L, Guo L, Zeng Y, Guo Q, Yang C, Shu J, Liu W, Yang L..  (2022)  Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells.,  75  [PMID:36395680] [10.1016/j.bmc.2022.117085]

Source

Source(1):

• Scientific Literature